Zanker B, Marx S, Strom T B, Köhler H
Medizinische Klinik und Poliklinik, Johannes-Gutenberg Universität, Mainz, F.R.G.
Int J Immunopharmacol. 1994 Jul;16(7):507-17. doi: 10.1016/0192-0561(94)90102-3.
In this study, the effect of verapamil, a phenylalkylamine-type Ca2+ antagonist, upon the activation of human mononuclear cells was investigated and a detailed analysis of the kinetics and dose related effects of verapamil upon alloreactive cytotoxic T-cells (CTL) was undertaken. Verapamil suppressed the release of interleukin-2, proliferation and generation of CTL activity in mitogen and alloantigen stimulated human T-lymphocytes in a dose related fashion. Verapamil suppressed the steady state levels of several T-cell activation-associated gene transcripts, i.e. the mRNA encoding for interleukin-2, and a cytotoxic T-cell specific serine esterase. Verapamil exerted a novel immune-suppressive effect, i.e. the inhibition of mature alloantigen-inducible cytolytic T-cells, thus rendering verapamil a progenitor of potent and clinically useful immunosuppressive drugs.
在本研究中,对苯烷基胺类钙离子拮抗剂维拉帕米对人单核细胞激活的影响进行了研究,并对维拉帕米对同种异体反应性细胞毒性T细胞(CTL)的动力学和剂量相关效应进行了详细分析。维拉帕米以剂量相关的方式抑制丝裂原和同种异体抗原刺激的人T淋巴细胞中白细胞介素-2的释放、增殖及CTL活性的产生。维拉帕米抑制了几种与T细胞激活相关基因转录本的稳态水平,即编码白细胞介素-2的mRNA和一种细胞毒性T细胞特异性丝氨酸酯酶。维拉帕米发挥了一种新的免疫抑制作用,即抑制成熟的同种异体抗原诱导的溶细胞性T细胞,从而使维拉帕米成为强效且具有临床应用价值的免疫抑制药物的先驱。